News and Trends 21 Jun 2023 FDA clears T-Cell receptor natural killer cell therapy for sarcoma Replay, a genome writing company, and The University of Texas MD Anderson Cancer Center (MD Anderson), have announced that the U.S. Food & Drug Administration (FDA) has issued a ‘safe to proceed’ for the Investigational New Drug (IND) application for NY-ESO-1 TCR/IL-15 NK, an engineered T-cell receptor natural killer (TCR-NK) cell therapy for advanced synovial […] June 21, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jun 2023 BIO International Convention 2023: The Highlights BIO International Convention, one of the largest networking events hosted for the biotech industry, has been influential in helping biopharmas discover new opportunities and building and strengthening partnerships within the biotech and pharma community. This year, the event took place from June 5 to 8, in the bustling biotech hotspot of Boston, Massachusetts, and saw […] June 20, 2023 - 14 minutesmins - By Dylan Kissane Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jun 2023 NodThera announces positive inflammatory disease data NodThera has announced positive data from first-in-human studies of its lead therapeutic candidates, NT-0249 and NT-0796. In the studies, both candidates were shown to clearly inhibit the NLRP3 inflammasome, a highly validated drug target that plays a pivotal role in controlling inflammatory diseases. The differentiated design characteristics of each candidate enabled them to penetrate different […] June 20, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jun 2023 Lighting up cancer: FluoGuide announces positive results from head & neck cancer trial FluoGuide A/S, a Danish biotech company, has announced positive interim results from the phase IIa trial of its lead product FG001 in head & neck cancer. FG001 was shown to illuminate tumors in all of the patients. Data show all 12 patients in the first two cohorts, undergoing surgery for head & neck squamous cell […] June 20, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jun 2023 FDA puts hold on Arcellx myeloma program following patient death Arcellx, Inc. has received notification from the U.S. Food and Drug Administration (FDA) that a clinical hold has been placed on its CART-ddBCMA investigational new drug (IND) for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). The clinical hold was received on June 16, following a recent patient death. The company said […] June 20, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jun 2023 Anoat raises funds to tackle cystic fibrosis Anoat Therapeutics, a French preclinical stage biotechnology company specialized in cystic fibrosis (CF), has raised €2 million ($2.17 million) in seed funding from AdBio partners. Anoat will use the funds to conduct additional in vivo and in vitro pharmacology assessments and select a lead candidate. Anoat Therapeutics’ goal is to bring a transformative and mutation-agnostic […] June 20, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jun 2023 Clearance for anti-tumor bispecific antibody trial TG ImmunoPharma Co., Ltd. (TGI), which focuses on the development of novel immuno-oncology therapies, says the FDA has granted clearance for the clinical trial of TGI-6, its bispecific antibody. TGI-6 targets unique tumor-associated antigens (TAA) and CD3 molecules simultaneously, enabling potent anti-tumor responses. TGI said the antibody demonstrates exceptional anti-tumor activity, favorable safety profiles, and […] June 20, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jun 2023 Allgenesis says dry eye patients’ trial data ‘encouraging’ Allgenesis Biotherapeutics Inc., a clinical-stage specialty pharmaceutical company focused on developing novel ophthalmic drugs, has announced topline data from its phase 1b clinical trial for AG-80308, a first-in-class, formyl peptide receptor (FPR) agonist formulated as an aqueous solution eye drop for the treatment of dry eye disease (DED). AG-80308 was considered safe at all doses […] June 19, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jun 2023 Trial shows colorectal cancer drug efficacy HUTCHMED (China) Limited and Takeda have announced results of their phase III FRESCO‑2 study evaluating fruquintinib in patients with previously treated metastatic colorectal cancer (CRC), which were published in The Lancet. Fruquintinib is a highly selective and potent inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3. FRESCO-2 is a global phase […] June 19, 2023 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jun 2023 Novartis acquires Chinook Therapeutics for $3.2B Novartis has entered into an agreement to acquire Chinook Therapeutics, a Seattle, Washington, based clinical stage biopharmaceutical company with two high-value, late-stage medicines in development for rare, severe chronic kidney diseases. The agreed deal, which is subject to customary closing conditions, is in line with Novartis’ strategy to focus on innovative medicines and will expand […] June 16, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jun 2023 Key regulator of COVID viral receptor may be new drug target Entry of the SARS-CoV-2 virus into human tissues depends on the activity of a host gene that regulates production of a key viral receptor, according to a study published in the open access journal PLOS Biology by Madison Strine and Craig Wilen of Yale University, U.S., and colleagues. The finding provides important new information on […] June 16, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jun 2023 Flamingo Therapeutics receives €1.7M to advance RNA-targeting oncology portfolio Flamingo Therapeutics has been awarded a research grant of €1.7 million ($1.9 million) by Flanders Innovation & Entrepreneurship (VLAIO). The award represents the funding at 60% of a €2.9 million ($3.2 million) project. Funding from the grant will be used to advance Flamingo Therapeutics’ RNA-targeting oncology portfolio, including translational research for its lead clinical program, […] June 16, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email